Quark Sees Nitto Denko Deal as 'Harbinger' of Future Partnerships
August 05, 2010
Quark Sees Nitto Denko Deal as 'Harbinger' of Future Partnerships
According to a company official, future deals, as with the one with Nitto Denko, will be driven by Quark's freedom to operate in the siRNA drugs space.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Lundbeck, Debiopharm Join List of Pharmas Looking to RNAi
February 3, 2011 / Gene Silencing News - Quark, Nitto Denko Collaborate on RNAi Drugs for Fibrotic Disease
July 15, 2010 / Gene Silencing News - Quark Begins Dosing Second Patient Subgroup in Phase I Study of Ocular Neuroprotection siRNA Drug
October 21, 2010 / Gene Silencing News - Snapshot: Partnership Goals, Track Records in the RNAi/miRNA Space
July 22, 2010 / Gene Silencing News - Quark Delayed Graft Function Drug Gets European Orphan Drug Status
June 17, 2010 / Gene Silencing News